I4907
Anti-IKKε/IKK-i, C-Terminal antibody produced in rabbit
~1.0 mg/mL, affinity isolated antibody, buffered aqueous solution
Synonym(s):
Anti-IKB Kinase
Sign Into View Organizational & Contract Pricing
Select a Size
About This Item
MDL number:
UNSPSC Code:
12352203
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen ~80 kDa
species reactivity
human
concentration
~1.0 mg/mL
technique(s)
western blot: 0.5-1 μg/mL
UniProt accession no.
application(s)
research pathology
shipped in
dry ice
storage temp.
−20°C
Gene Information
human ... IKBKE(9641)
General description
IKK-epsilon/IKK-I belongs to IκB kinase complex and express mainly in immune cells. IKK-I express in response to proinflammatory cytokines such as tumor necrosis factor-α, IL-, IL-6 and stimulate NF-κB activation, hence referred as inducible IκB kinase . Polyclonal anti-IKK epsilon/IKK-I c-terminal antibody can be used in immunoblotting to detect human IKK epsilon/IKK-I. Anti-IKK epsilon/IKK-I antibodies can react specifically with human IKK epsilon/IKK-I and show no cross reactivity with IKK α, IKK β and IKK γ.
Immunogen
Synthetic peptide corresponding to amino acids 701-716 of human IKK-epsilon/IKK-I conjugated to KLH.
Application
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)
Western Blotting (1 paper)
Polyclonal anti-IKK epsilon/IKK-I c-terminal antibody can be used in immunoprecipitation and western blot.
Biochem/physiol Actions
The antibody show no cross-reactivity to IKKα, IKKβ, or IKKγ.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Solution in phosphate buffered saline containing 0.02% sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
常规特殊物品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Suhu Liu et al.
Blood advances, 2(23), 3428-3442 (2018-12-07)
To identify novel therapeutic targets in acute myeloid leukemia (AML), we examined kinase expression patterns in primary AML samples. We found that the serine/threonine kinase IKBKE, a noncanonical IkB kinase, is expressed at higher levels in myeloid leukemia cells compared
Israel Cañadas et al.
Nature medicine, 24(8), 1143-1150 (2018-07-25)
Mesenchymal tumor subpopulations secrete pro-tumorigenic cytokines and promote treatment resistance1-4. This phenomenon has been implicated in chemorefractory small cell lung cancer and resistance to targeted therapies5-8, but remains incompletely defined. Here, we identify a subclass of endogenous retroviruses (ERVs) that
R T Peters et al.
Molecular cell, 5(3), 513-522 (2000-07-06)
Here we report the identification of a novel PMA-inducible IkappaB kinase complex, distinct from the well-characterized high-molecular weight IkappaB kinase complex containing IKKalpha, IKKbeta, and IKKgamma. We have characterized one kinase from this complex, which we designate IKKepsilon. Although recombinant
Carrie D House et al.
BMC cancer, 18(1), 595-595 (2018-05-29)
Metastatic breast cancer carries a poor prognosis despite the success of newly targeted therapies. Treatment options remain especially limited for the subtype of triple negative breast cancer (TNBC). Several signaling pathways, including NF-κB, are altered in TNBC, and the complexity
Marianne K Kim et al.
Oncotarget, 5(24), 12788-12802 (2014-12-05)
Ovarian cancer (OC) is extremely heterogeneous, implying that therapeutic strategies should be specifically designed based on molecular characteristics of an individual's tumor. Previously, we showed that IKKε promotes invasion and metastasis in a subset of OCs. Here, we identified CHEK1
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service